Neovasc Inc. Reports Second Quarter 2009 Financi...(----------------------- GROSS PROFIT ...),Health

Date:8/19/2009

----------------------- GROSS PROFIT 323,059 212,717 528,783 437,942 ------------------------------------------------------------------------- EXPENSES Selling 163,683 785,491 466,568 1,534,995 General and administration 659,004 779,363 1,409,833 1,317,648 Product development and clinical trials 864,702 414,958 1,741,482 1,036,703 Inventory write down - 94,404 - 94,404 Amortization 31,103 75,670 63,459 121,436 ------------------------------------------------------------------------- 1,718,492 2,149,886 3,681,342 4,105,186 ------------------------------------------------------------------------- LOSS BEFORE OTHER INCOME (EXPENSES) (1,395,433) (1,937,169) (3,152,559) (3,667,244) ------------------------------------------------------------------------- OTHER INCOME (EXPENSES) Interest income 1,355 14,208 10,976 23,303 Interest on long-term debt (2,276) (5,021) (5,529) (12,535) Accreted interest on repayable contribution agreement - (3,846) - (7,685) Gain (Loss) on foreign exchange 65,903 16,155 70,421 6,913 ------------------------------------------------------------------------- 64,982 21,496 75,868 9,996 ------------------------------------------------------------------------- NET LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD (1,330,451) (1,915,673) (3,076,691) (3,657,248) DEFICIT, BEGINNING OF PERIOD (61,636,203) (27,371,973) (59,889,963) (25,630,398)
'/>"/>

SOURCE Neovasc Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. Neovasc Inc. Reports Year 2008 Financial Results
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
9. Neovasc Inc. Reports First Quarter 2009 Financial Results
10. Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites